Predict your next investment

Dana Farber Cancer Institute company logo
Corporation
HEALTHCARE | Medical Facilities & Services / Hospitals
dana-farber.org

See what CB Insights has to offer

Investments

1

Portfolio Exits

2

Funds

2

Partners & Customers

10

About Dana Farber Cancer Institute

Dana-Farber Cancer Institute is committed to providing care to children and adults with cancer, while advancing the understanding, treatment, cure, and prevention of cancer and related diseases.

Dana Farber Cancer Institute Headquarter Location

450 Brookline Avenue

Boston, Massachusetts, 02215,

United States

617-632-3000

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Dana Farber Cancer Institute Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Dana Farber Cancer Institute Rank

Latest Dana Farber Cancer Institute News

Advance in understanding cell division could lead to new cancer treatments

May 4, 2022

Credit: Pixabay/CC0 Public Domain A protein called CDC7, long thought to play an essential role early in the cell division process, is in fact replaceable by another protein called CDK1, according to a study by investigators at Weill Cornell Medicine and the Dana Farber Cancer Institute. The finding represents a fundamental advance in cell biology and may lead to new cancer therapies, since cancers frequently alter the molecular machinery of cell division to sustain their rapid growth. The study, published online May 4 in Nature, determined the effects of removing CDC7 in a variety of mammalian cell types, a process that has been difficult to achieve. The results suggest that simultaneously targeting CDC7 and CDK1 could be an effective cancer treatment strategy. "This study provides new insight into one of the most important steps in cell division and suggests a new set of targets for future cancer therapies," said Dr. Tobias Meyer, the Joseph Hinsey Professor in Cell and Developmental Biology and a member of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine. The other co-senior author of the study is Dr. Peter Sicinski, professor of genetics at Harvard Medical School and a researcher at Dana-Farber Cancer Institute, and the first authors are Dr. Jan Suski, a postdoctoral fellow in the Sicinski Lab at Dana-Farber, and Nalin Ratnayeke, a senior graduate student in the Meyer Lab at Weill Cornell Medicine. The process of cell division, also called the cell cycle, is of central importance in biology. As scientists have learned in recent decades, this process is initiated and controlled by a large set of molecules including the signaling proteins CDK1, CDK4, CDK6 and CDC7. Much is already known about how these proteins orchestrate the start of cell division, and cancer drugs that block cell division by blocking both CDK4 and CDK6 are already in use. But the cell cycle roles of CDK1 and CDC7 have been somewhat murky. Based on prior experiments primarily in yeast cells , CDC7 was thought to be broadly essential for a key initial step in cell division—moving the cell from the preparatory phase of the cell cycle, called "G1," into the "S" phase wherein the cell duplicates its DNA and becomes committed to dividing. In the new study, the researchers used a variety of new and established protein -removal methods to make a surprising discovery: Selectively deleting the mouse version of CDC7 in different cell types may slow or stop cell division, but only for a day or two before cell division resumes. The researchers found that cells in mice, and presumably in all mammals, can compensate for the loss of CDC7 with increased activity from CDK1—even though the latter is structurally very different from CDC7 and had been thought to have a completely separate role in cell division . The findings illuminate the complex molecular orchestration of the cell cycle, and suggest that simultaneously blocking both CDC7 and CDK1 could be a powerful new strategy against cancer . The researchers are now continuing to tease apart the roles of the different molecular actors in the cell cycle . "This work highlights the surprising fact that cells can sometime achieve redundancy for a given function with two very different classes of protein—not just with two closely related proteins as we're used to seeing," Dr. Meyer said. Explore further

Dana Farber Cancer Institute Investments

1 Investments

Dana Farber Cancer Institute has made 1 investments. Their latest investment was in Kojin Therapeutics as part of their Series A on June 6, 2021.

CBI Logo

Dana Farber Cancer Institute Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

6/9/2021

Series A

Kojin Therapeutics

$60M

Yes

10

Date

6/9/2021

Round

Series A

Company

Kojin Therapeutics

Amount

$60M

New?

Yes

Co-Investors

Sources

10

Dana Farber Cancer Institute Portfolio Exits

2 Portfolio Exits

Dana Farber Cancer Institute has 2 portfolio exits. Their latest portfolio exit was C4 Therapeutics on October 02, 2020.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

10/2/2020

IPO

C4 Therapeutics

$99M

Public

2

1/1/2016

Spinoff / Spinout

Subscribe to see more

$99M

Subscribe to see more

10

Date

10/2/2020

1/1/2016

Exit

IPO

Spinoff / Spinout

Companies

C4 Therapeutics

Subscribe to see more

Valuation

$99M

$99M

Acquirer

Public

Subscribe to see more

Sources

2

10

Dana Farber Cancer Institute Acquisitions

1 Acquisition

Dana Farber Cancer Institute acquired 1 company. Their latest acquisition was Commonwealth Hematology-Oncology on July 01, 2014.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

7/1/2014

$99M

Acquired

1

Date

7/1/2014

Investment Stage

Companies

Valuation

$99M

Total Funding

Note

Acquired

Sources

1

Dana Farber Cancer Institute Fund History

2 Fund Histories

Dana Farber Cancer Institute has 2 funds, including Dana-Farber Innovations Research Fund.

Closing Date

Fund

Fund Type

Status

Amount

Sources

2/26/2020

Dana-Farber Innovations Research Fund

$26M

2

Binney Street Capital

10

Closing Date

2/26/2020

Fund

Dana-Farber Innovations Research Fund

Binney Street Capital

Fund Type

Status

Amount

$26M

Sources

2

10

Dana Farber Cancer Institute Partners & Customers

10 Partners and customers

Dana Farber Cancer Institute has 10 strategic partners and customers. Dana Farber Cancer Institute recently partnered with SpringWorks Therapeutics on October 10, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

10/1/2021

Licensee

United States

SpringWorks Therapeutics Reports Third Quarter 2021 Financial Results and Recent Business Highlights

In October 2021 , SpringWorks Therapeutics , Inc. announced an update from its ongoing clinical collaboration with GlaxoSmithKline evaluating nirogacestat in combination with BLENREP in patients with relapsed or refractory multiple myeloma .

1

9/8/2021

Partner

United States

1

2/11/2021

Partner

United States

1

9/17/2020

Partner

United States

Subscribe to see more

Subscribe to see more

10

8/4/2020

Partner

United States

Subscribe to see more

Subscribe to see more

10

Date

10/1/2021

9/8/2021

2/11/2021

9/17/2020

8/4/2020

Type

Licensee

Partner

Partner

Partner

Partner

Business Partner

Country

United States

United States

United States

United States

United States

News Snippet

SpringWorks Therapeutics Reports Third Quarter 2021 Financial Results and Recent Business Highlights

In October 2021 , SpringWorks Therapeutics , Inc. announced an update from its ongoing clinical collaboration with GlaxoSmithKline evaluating nirogacestat in combination with BLENREP in patients with relapsed or refractory multiple myeloma .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

1

1

10

10

Dana Farber Cancer Institute Team

21 Team Members

Dana Farber Cancer Institute has 21 team members, including current Chief Executive Officer, Edward J Benz.

Name

Work History

Title

Status

Edward J Benz

Chief Executive Officer

Current

William Hahn

Chief Operating Officer

Current

Kate McDaniel

Chief People Officer, Senior Vice President

Current

Kelly Maxwell

Akin Gump Strauss Hauer & Feld

Chief Compliance Officer

Current

Craig Bunnell

Chief Medical Officer

Current

Name

Edward J Benz

William Hahn

Kate McDaniel

Kelly Maxwell

Craig Bunnell

Work History

Akin Gump Strauss Hauer & Feld

Title

Chief Executive Officer

Chief Operating Officer

Chief People Officer, Senior Vice President

Chief Compliance Officer

Chief Medical Officer

Status

Current

Current

Current

Current

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.